Fact CheckerSign in

NCT07225738Recruiting

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

Source: ClinicalTrials.gov · Last updated 20 Feb 2026

Brief summary (registry, in English)

This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

Status (registry)
Recruiting
Study type
Observational
Enrollment
700 (estimated)
First submitted
16 Oct 2025
Start date
21 Jan 2026
Primary completion date
22 Aug 2030
Lead sponsor
City of Hope Medical Center
NCT number
NCT07225738

What you commit to

  • Study type: Observational
  • Planned participants: 700
  • From 21 Jan 2026 to the primary completion date, 22 Aug 2030
  • 11 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • \* Patients may not have completed five cycles of first line therapy or undergone any second line therapy
    • Other active malignancy
    • Patients may not have undergone autologous hematopoietic stem cell transplantation
    • Unable to comply with the study assessments
    • HCP SURVEY: Reports directly to study PI (Dr. Richard Lee)
    • HCP SURVEY: Member of the study team or involved in survey design or analysis
    • HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses

Who the study is looking for

  • \* Documented informed consent of the participant
    • Age: ≥ 18 years
    • ECOG ≤ 3
    • Ability to read and understand English
    • Patient must be newly diagnosed with a histologically confirmed multiple myeloma
    • Patients may have started first line therapies and received up to four cycles
    • HCP SURVEY: Documented informed consent of the participant
    • HCP SURVEY: Age: ≥ 18 years
    • HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse
    • HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients
    • HCP SURVEY: Able to read and understand English
    • HCP SURVEY: Affiliation with City of Hope

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (11)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
City of Hope Medical Center
Coordinator of this site? Confirm its status
DuarteUnited StatesRecruiting
CTCA at Western Regional Medical Center
Coordinator of this site? Confirm its status
GoodyearUnited StatesNot yet recruiting
City of Hope Seacliff
Coordinator of this site? Confirm its status
Huntington BeachUnited StatesNot yet recruiting
City of Hope at Irvine Lennar
Coordinator of this site? Confirm its status
IrvineUnited StatesRecruiting
City of Hope at Long Beach Elm
Coordinator of this site? Confirm its status
Long BeachUnited StatesNot yet recruiting
City of Hope Atlanta Cancer Center
Coordinator of this site? Confirm its status
NewnanUnited StatesNot yet recruiting
City of Hope at Newport Beach Fashion Island
Coordinator of this site? Confirm its status
Newport BeachUnited StatesNot yet recruiting
City of Hope South Pasadena
Coordinator of this site? Confirm its status
South PasadenaUnited StatesNot yet recruiting
City of Hope Upland
Coordinator of this site? Confirm its status
UplandUnited StatesNot yet recruiting
City of Hope West Covina
Coordinator of this site? Confirm its status
West CovinaUnited StatesNot yet recruiting
City of Hope at Chicago
Coordinator of this site? Confirm its status
ZionUnited StatesNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.